Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to
The post FDA approves Roche’s Xofluza to treat influenza appeared first on Pharma Business review.
Original Article: FDA approves Roche’s Xofluza to treat influenza